10-Q: Eli Lilly's Q3 2026 Revenue Soars on Mounjaro & Zepbound

Eli Lilly reports a significant 39% revenue increase to $24.4 billion for Q3 2026, driven by strong performance in Mounjaro and Zepbound, alongside substantial net income growth.

Summary

• Eli Lilly reported Q3 2026 revenue of $24.4 billion, a 39% increase year-over-year, and net income of $6.45 billion, up 16%.
• For the first nine months of 2026, revenue reached $67.2 billion, a 46% increase, with net income rising 50% to $20.9 billion.
• The strong performance was primarily driven by increased volume of Mounjaro and Zepbound, despite some realized price decreases.
• Acquisitions, including Kelonia Therapeutics, Centessa Pharmaceuticals, and Ventyx Biosciences, significantly contributed to growth, with substantial acquired IPR&D charges.
• The company is making significant investments in manufacturing capacity to meet anticipated demand for its products.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strongly positive filing, driven by exceptional revenue growth and net income increases, largely fueled by the success of key products like Mounjaro and Zepbound.

Positives

• Revenue increased by 39% to $24.4 billion for the three months ended September 30, 2026, and by 46% to $67.2 billion for the nine months ended September 30, 2026.
• Net income rose by 16% to $6.45 billion for the three months ended September 30, 2026, and by 50% to $20.9 billion for the nine months ended September 30, 2026.
• Diluted earnings per share increased by 16% to $7.22 for the three months ended September 30, 2026, and by 51% to $23.42 for the nine months ended September 30, 2026.
• Mounjaro and Zepbound sales showed significant growth, with Mounjaro revenue up 65% and Zepbound up 49% in Q3 2026 compared to Q3 2025.
• Gross margin improved to 83.9% for Q3 2026 from 82.9% in the prior year period, indicating improved production costs and product mix.
• The company has a strong liquidity position with $4.9 billion in cash and cash equivalents and $4.1 billion in investments as of September 30, 2026.
• Significant progress in clinical development pipeline with FDA approvals for insulin efsitora alfa (Onswik) and orforglipron (Foundayo), and positive Phase 3 trial results for retatrutide.

Negatives

• Acquired in-process research and development (IPR&D) charges significantly increased to $4.18 billion in Q3 2026 from $656 million in Q3 2025, and to $7.54 billion for the nine months from $2.38 billion.
• Asset impairment, restructuring, and other special charges increased to $1.3 billion for the nine months ended September 30, 2026, from $400 million in the prior year period.
• Effective tax rate increased to 23.3% for Q3 2026 and 21.0% for the nine months, primarily due to the unfavorable tax impact of nondeductible acquired IPR&D charges.
• Total debt increased to $49.5 billion as of September 30, 2026, from $42.5 billion as of December 31, 2025.

Risks

• Intense competition affecting products, pipeline, or industry.
• Continued pricing pressures and actions by governmental and private actors affecting pricing, reimbursement, and patient access.
• Uncertainty in the outcome of acquisitions and business development transactions.
• Dependence on relatively few products or product classes for a significant percentage of total revenue.
• Expiration of intellectual property protection and competition from generic and biosimilar products.
• Issues with product supply, regulatory approvals, or negative outcomes stemming from manufacturing difficulties or disruptions.
• Litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property.
• Regulatory changes, developments, and uncertainty, including potential impacts from the Inflation Reduction Act (IRA) on drug pricing.

Future Outlook

The company expects its near-term financial performance to be impacted by the timing of potential regulatory approvals for orforglipron, as well as demand and uptake in new incretin channels and markets. Manufacturing expansion initiatives are underway to support anticipated demand for current and future products.

Management Comments

• Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.
• We have entered into voluntary agreements with the U.S. government in which, among other arrangements, we agreed to lower Medicaid and certain other drug prices for U.S. patients and to launch new medicines with a more balanced pricing approach across developed nations.
• The Inflation Reduction Act of 2022 (IRA) has, and will continue to, meaningfully influence our business strategies and those of our competitors and could significantly impact our business and consolidated results of operations.
• We continue to see the production, marketing, and sale of counterfeit, misbranded, adulterated, and mass-compounded incretins. These practices may impact patient safety and undermine regulatory drug approval processes.
• We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements.

Industry Context

StockSavvy.ai notes that Eli Lilly's performance is strongly aligned with the growing market for GLP-1 agonists and related therapies for cardiometabolic health and obesity, a trend also seen across major pharmaceutical competitors. The company's significant investments in R&D and manufacturing reflect the high demand and competitive landscape in this therapeutic area.

Comparison to Industry Standards

• Eli Lilly's revenue growth of 39% in Q3 2026 significantly outpaces the average revenue growth for large pharmaceutical companies, which typically ranges from low to mid-single digits.
• The company's net income growth of 16% in Q3 2026 and 50% for the nine-month period is also considerably higher than industry averages, reflecting strong operational leverage and product success.
• The substantial increase in R&D expenses (23% for Q3 2026) aligns with industry trends of heavy investment in pipeline development, though Lilly's absolute spend is substantial.
• The significant increase in acquired IPR&D charges reflects an aggressive M&A strategy, which is common in the pharmaceutical sector for pipeline enhancement, but Lilly's scale of these charges is notable.

Legal Proceedings

• Emgality Patent Litigation: U.S. Court of Appeals reversed a trial court's finding of invalidity, remanding the case.
• Verzenio Hatch-Waxman Litigation: Patent infringement action filed against Cipla Ltd. for generic version of Verzenio, trial scheduled for May 2028.
• Tirzepatide Hatch-Waxman Litigation: Patent infringement actions filed against multiple generic companies for Mounjaro and/or Zepbound.
• 340B Litigation and Investigations: Ongoing lawsuits and inquiries related to the 340B program and contract pharmacy policies.
• Insulin Pricing Litigation: Lawsuits related to insulin pricing and rebates, largely consolidated in multidistrict litigation.
• Pricing Investigations: Investigations and information requests from governmental entities regarding drug pricing and average manufacturer price calculations.
• Actos Litigation: Third-party payer class action alleging concealment of bladder cancer risk.
• Mounjaro, Trulicity, and Zepbound Product Liability Litigation: Lawsuits alleging various injuries following use of incretin medicines, coordinated in federal MDLs.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and net income growth, increased EPS, and ongoing share repurchase program.
• Employees: Continued investment in R&D and manufacturing may lead to job creation and growth opportunities.
• Customers/Patients: Potential for increased access to innovative medicines, but also concerns regarding pricing and affordability due to regulatory pressures.
• Suppliers: Increased demand for products may lead to greater business opportunities for suppliers.
• Creditors: Increased debt levels may be a concern, but strong cash flow generation mitigates risk.

Next Steps

• Continue manufacturing expansion initiatives to meet anticipated demand.
• Monitor and manage the impact of regulatory developments, including the Inflation Reduction Act.
• Continue engagement with Centers for Medicare & Medicaid Services on long-term Medicare access to obesity medicines.
• Pursue further regulatory approvals and market launches for orforglipron (Foundayo) for type 2 diabetes.
• Initiate and progress Phase 3 trials for various compounds including retatrutide, baricitinib, eloralintide, brenipatide, sofetabart mipitecan, and tersolisib.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance driven by blockbuster drugs, a robust pipeline with multiple late-stage assets, and strategic acquisitions. Despite increased R&D and IPR&D expenses, the company's revenue and profit growth significantly exceed industry benchmarks, indicating strong execution and market leadership. The risks are well-managed and typical for the industry, while the positives strongly outweigh them.

Keywords

Mounjaro, Zepbound, Tirzepatide, Orforglipron, Foundayo, Cardiometabolic Health, Obesity, Diabetes